HOUSTON INNOVATORS PODCAST EPISODE 33

Online camp and programming marketplace pivots amid pandemic to help Houston parents

Tudor Palaghita has advanced his startup, Camppedia, so that parents can have virtual and in-person activities for their kids this summer. Photo courtesy of Camppedia

This summer was supposed to be Houston-based Camppedia's breakout moment — a chance for CEO and Founder Tudor Palaghita to prove the company's value to its users. Palaghita is still getting to provide a much needed service to parents looking to enroll their children into enriching summer programs, but in a much different capacity thanks to COVID-19.

Camppedia — which Palaghita founded with his sister, Ana, in late 2018 — is an online marketplace that acts as a one-stop shop for parents looking for and managing local programming and activities for their kids. As the pandemic began to derail after school activities and summer plans, Palaghita quickly pivoted to provide essential needs like virtual offerings and connecting community members with new resources.

"If anything, the pandemic forced us to move a lot of things forward," Palaghita says about some of the key implementations he's made to the site. "The focus on the community was also something coming earlier than planned, but it was the most wonderful thing to come out of this. It really feels like everybody came together to give and to help each other."

Camppedia's business model is to give local camp and program providers — mostly small businesses, Palaghita says — a place to seamlessly reach parents. Now, these providers need Camppedia's platform more than ever as parents seek options a as they return to work or continue to look for at-home entertainment for their kids.

In order to better inform providers with what parents are looking for, Palaghita created a survey for parents to express what their concerns are, including when they are ready for in-person camps, what kind of safety measures they want to see, what are their thoughts on virtual programs are, and more.

"We're helping the community understand what parents think so that we can provide the best avenues and information and so providers can tune their programs to meet those needs," Palaghita says on this week's episode of the Houston Innovators Podcast.

Palaghita shares how he's managed throughout the pandemic and his plans for growing Camppedia throughout these challenges. Listen to the full interview with Palaghita below — or wherever you get your podcasts — and subscribe for weekly episodes.


Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News